Food noise came back at month seven. Is that tolerance, and does it mean the dose has to go up?

Months two through six were the quietest my head has been about food since childhood. Around month seven it started coming back, and now at month nine it is maybe 40% of what it was pre-treatment. Weight has been flat for six weeks.

The obvious interpretation is tolerance and the obvious action is more drug. But I have read that the trials maintained their effect for a year or two at a fixed dose, which does not sound like a drug that develops tolerance. So either the trial populations were different from me, or the trials were measuring something other than what I am experiencing, or "tolerance" is the wrong word for what is happening.

What are the candidate explanations, and is there a way to work out which one applies to me before I make a decision about the dose? I would rather not escalate on a wrong diagnosis and end up higher up the ladder with the same problem.

"Tolerance" is probably the wrong word, and there are four distinct candidate mechanisms with different implications. Only one of them is addressed by more drug.

The four candidates

1. Counter-regulation. You have lost weight, and weight loss itself increases orexigenic signalling: ghrelin rises, leptin falls, and the drive being opposed gets stronger. The drug is producing the same effect against a larger opposing force, so the net result is smaller. Nothing about the drug has changed. This is the most likely single explanation for a month-seven return and it is the one most consistent with the trial data, because the trials show the effect persisting while also showing the weight curve flattening.
2. Loss of the aversion component. If part of your month-two quiet was low-grade nausea rather than reduced salience, that part was always going to fade, because the emetic and gastric pathways are tachyphylactic. What returns is not food noise being generated anew, it is the removal of a suppressor. See the question above on distinguishing the two.
3. Behavioural accommodation. Habits reassert themselves. Cue exposure resumes, meal structure loosens, grazing returns, evening eating comes back. The salience-reducing effect is intact but you have reintroduced the cues it was protecting you from. This one is invisible from the inside because none of the individual changes feel significant.
4. Genuine pharmacological tolerance at the receptor level. Least supported of the four for this class. The pivotal trials maintained weight effect at fixed dose for 68 and 104 weeks, which is difficult to reconcile with substantial receptor-level desensitisation. Not impossible, and individual variation exists, but it should be the last hypothesis rather than the first.

How to tell them apart

That last row is the one I would start with, and it is the one your post does not answer. Six weeks of flat weight tells us your intake now matches your expenditure. It does not tell us whether intake rose or expenditure fell, and those have different solutions. Weigh your food for two weeks before deciding anything.

On the dose question

Escalating is defensible for candidate 1 and for candidate 4. It is close to useless for candidate 3, and for candidate 2 it works by reintroducing the aversion, which is a bad trade dressed up as an improvement. Given that accommodation and counter-regulation are the two most likely explanations, the order I would work through is:

1. Measure intake properly for two weeks. No changes.
2. Audit structure: meal times, grazing, evening eating, liquid calories, cue exposure. Restore whatever has drifted. Give it four weeks.
3. Check the day 5-7 pattern. If the effect clearly fades late in the week, the issue is exposure at the trough, and that is a dose or interval conversation rather than a tolerance one.
4. Only then discuss escalation, and frame it to your prescriber as "the appetite effect has diminished and here is the evidence" rather than "the weight has stopped moving", because those support different decisions.

One more consideration. 40% of your pre-treatment food noise, at a weight you have held for six weeks, may simply be the sustainable long-run state rather than a problem to be solved. The trials show mean weight plateauing and, over longer follow-up, creeping slightly upward on treatment. Expecting the month-three experience to be permanent is the mistake; a partial, durable effect at a stable weight is what success looks like in this class.

Worth adding the boring explanations that get skipped because they are boring, and which account for a real fraction of "it stopped working" reports:

• Product integrity. If your material changed batch, vendor or handling at any point, that is a candidate before any neurobiology. Peptides degrade with heat and with agitation, and freeze-thaw cycling reduces potency. A step-change loss of effect that coincides with starting a new vial is a supply question, not a tolerance question. If you have a certificate of analysis for the current batch and not the previous one, or vice versa, that asymmetry is worth noting. Independent testing through Janoshik, Medutest, PeptideMeter or VendorInvestigate is the only way to actually resolve it rather than speculate.
• Reconstitution and dosing arithmetic. Recheck the maths on your current vial from scratch. Concentration errors after a change in diluent volume are a common and completely silent cause of under-dosing, and dead space in a syringe is a proportionally larger loss at small volumes.
• Storage. Reconstituted material left at room temperature for extended periods, or a refrigerator door shelf that cycles warm, will lose potency over weeks in a way that looks exactly like gradual tolerance.
• Injection site and technique. Consistently injecting into scar tissue or repeatedly into the same site can alter absorption. Rotating sites is standard for a reason.
• Sleep. Two weeks of short sleep raises appetite and cue reactivity measurably and is a strong candidate for a change that feels pharmacological. Check whether the month-seven return coincided with anything in your life rather than assuming it originated in the vial.
• Alcohol. Increased alcohol intake raises subsequent-day food intake and specifically raises cue-driven eating. If drinking rose around month seven, that is worth examining.

These are unglamorous and they are also cheap to check, which makes them the right first pass. Research-use-only material is not approved for human use and none of the above is a recommendation about your own dosing; it is a list of things that make a nominally fixed dose stop being a fixed dose.

One reframe that helped me when I went through this at about the same timepoint: the month-two-to-six experience was not the drug working correctly and everything since is not decline. The early period is an outlier produced by the coincidence of several things that do not persist.

What is stacked in months two to six, and what happens to each:

• Peak novelty and vigilance. You are tracking, motivated, and attentive. Fades in everyone, on every intervention, always.
• Peak aversion, from side effects that have not yet attenuated. Fades reliably.
• Minimum counter-regulation, because you have not yet lost much weight. Grows as you lose.
• Rapidly falling weight providing continuous positive feedback. Decelerates by construction.
• The salience-reduction effect. Largely persists.

Four of those five were always temporary. So the return of some food noise at month seven is close to the expected trajectory rather than a deviation from it, and the useful question is not how to get back to month three but what a sustainable long-run configuration looks like.

What that configuration looks like in practice, from people who have held losses for a couple of years: a partial appetite effect from a stable dose, structural eating habits that do not depend on the drug doing all the work, resistance training two or three times a week, protein intake that is deliberate rather than incidental, and an accepted maintenance weight rather than a target that keeps moving down. None of that is as pleasant as month three. All of it is still there in month thirty.